HIV fusion inhibitor
Enfuvirtide
Brand names: Fuzeon
Adult dose
Dose: 90mg SC BD
Route: Subcutaneous
Frequency: BD
Clinical pearls
- Salvage therapy for treatment-experienced HIV with multi-drug resistance
- Largely superseded by INSTI-based regimens; specialist HIV use
- BHIVA / EACS treatment guidelines
Contraindications
- Hypersensitivity
Side effects
- Injection-site reactions (almost universal — induration, erythema, nodules)
- Pneumonia (rare)
- Hypersensitivity reactions
- Eosinophilia
Interactions
- No clinically significant CYP interactions
Monitoring
- Viral load
- CD4
- Injection-site review
Reference: BNF; BHIVA HIV guidelines; EACS; https://bnf.nice.org.uk/drugs/enfuvirtide/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023